Search Results
Feb 17, 2026, 11:25 ET New Treatment Modalities Are Reaching Cancers That Resisted Everything Else
providing approximately 13 additional weeks of follow-up since the prior ESMO presentation. Among 23 evaluable patients in Cohort 2 receiving 5.0 mCi, nine (39%) achieved objective response per RECIST v1.1 regardless of SSTR2 expression profile, and 76% of the 25 total evaluable patients remained progression-free
More news about: Equity Insider
Feb 17, 2026, 11:17 ET New Treatment Modalities Are Reaching Cancers That Resisted Everything Else
providing approximately 13 additional weeks of follow-up since the prior ESMO presentation. Among 23 evaluable patients in Cohort 2 receiving 5.0 mCi, nine (39%) achieved objective response per RECIST v1.1 regardless of SSTR2 expression profile, and 76% of the 25 total evaluable patients remained progression-free
More news about: Equity Insider
Feb 17, 2026, 07:00 ET Costa Rica to Host Latin America's Leading MedTech Forum
sciences solution providers: Enhanced Compliance Inc. (ECI), Grupo Vargas, Inventory and Distribution Services (IDS), Microbiología y Calidad Industrial (MCI), Operaciones e Ingeniería de Avanzada (OPIA), and Electrotécnica. As strategic partners of CINDE, they share a common vision: to accelerate growth and
More news about: CINDE
Feb 12, 2026, 11:30 ET ALTOUR Strengthens Leadership Team to Advance Growth and Industry Excellence
MICE, bringing over 25 years of experience leading strategic growth across meetings, incentives, conferences, and events. Having held a senior role at MCI, Bill is known for his client-centric approach and ability to deliver impactful experiences for global associations and corporations. His leadership
More news about: ALTOUR
Feb 10, 2026, 06:05 ET WESCO International, Inc. Announces Upcoming Retirement of Dave Schulz, EVP and CFO, and Appointment of Indraneel Dev as EVP and CFO
Mr. Dev served as Chief Financial Officer of Lumen Technologies. He previously held various senior finance leadership roles at Level 3 Communications, MCI, and MFS Communications. Mr. Dev holds a B.A. in Mathematics from the University of Delhi (India) and an MBA from the University of Arizona, and he is
More news about: Wesco International
Feb 09, 2026, 01:07 ET BLA for subcutaneous formulation of Leqembi® designated for Priority Review in China
overall Alzheimer's disease treatment care pathway.Eisai estimates that in 2024 there were 17 million patients with Mild Cognitive Impairment (MCI) or mild dementia due to Alzheimer's disease in China, a number that is expected to rise as the population ages.Leqembi was launched in China
More news about: BioArctic
Feb 09, 2026, 01:04 ET BLA for subcutaneous formulation of Leqembi® designated for Priority Review in China
overall Alzheimer's disease treatment care pathway.Eisai estimates that in 2024 there were 17 million patients with Mild Cognitive Impairment (MCI) or mild dementia due to Alzheimer's disease in China, a number that is expected to rise as the population ages.Leqembi was launched in China
More news about: BioArctic
Feb 04, 2026, 11:39 ET Mazda registra los terceros mejores resultados de ventas de su historia en enero
28,958 vehículos vendidos.Mejores ventas históricas en enero del modelo CX-50, con 10,415 vehículos vendidos.Mazda Canada, Inc. (MCI) registró ventas en enero de 4,974 vehículos, lo que representa un aumento del 4.9 por ciento en comparación con igual mes del año anterior. Mazda
More news about: Mazda North American Operations
Feb 03, 2026, 10:05 ET Mazda Reports Third Best January Sales Results
January sales with 28,958 vehicles sold.Best-ever January sales of CX-50 sales with 10,415 vehicles sold.Mazda Canada, Inc., (MCI) reported January sales of 4,974 vehicles, an increase of 4.9 percent compared to January last year. Mazda Motor de Mexico (MMdM) reported January
More news about: Mazda North American Operations
Jan 30, 2026, 10:19 ET $668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors
progression-free and alive."The updated interim results presented at ASCO-GI continue to support VMT-α-NET's compelling overall clinical profile at the 5 mCi dose," said Markus Puhlmann, Chief Medical Officer of Perspective Therapeutics. "With the robust clinical dataset being accrued from strong patient
More news about: USA News Group
Jan 26, 2026, 16:13 ET Eisai submits Marketing Authorisation Variation to EMA for intravenous maintenance dosing every four weeks with Leqembi® (lecanemab)
dosing for lecanemab. In the EU, lecanemab is indicated for the treatment of patients with a clinical diagnosis of mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease (early Alzheimer's disease) who are apolipoprotein E ε4 (ApoE ε4[1]) non-carriers or heterozygotes
More news about: BioArctic
Jan 25, 2026, 21:48 ET Leqembi® Iqlik™ (lecanemab-irmb) supplemental Biologics License Application regarding subcutaneous starting dose granted Priority Review by the US FDA
the U.S. Food and Drug Administration (FDA). Leqembi is indicated for the treatment of Alzheimer's disease in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early Alzheimer's disease). A Prescription Drug User Fee Act (PDUFA) action date is set
More news about: BioArctic
Jan 25, 2026, 21:45 ET Leqembi® Iqlik™ (lecanemab-irmb) supplemental Biologics License Application regarding subcutaneous starting dose granted Priority Review by the US FDA
the U.S. Food and Drug Administration (FDA). Leqembi is indicated for the treatment of Alzheimer's disease in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early Alzheimer's disease). A Prescription Drug User Fee Act (PDUFA) action date is set
More news about: BioArctic
Jan 25, 2026, 18:30 ET FDA Accepts LEQEMBI® IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
LEQEMBI IQLIK, as a weekly starting dose. LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). The sBLA has been granted Priority Review, with a Prescription Drug User Fee
More news about: Eisai Inc.
Jan 23, 2026, 11:51 ET Ace Hardware and Menards Deliver the Best DIYers' Customer Experience in 2025 Market Force Study
theatres, fitness, financial services, gaming, CPG, alcohol and tobacco, pharma, government agencies and more. Market Force is part of the MCI family of companies, alongside MCI BPO and AiCX. Learn more at:
More news about: Market Force Information
Jan 13, 2026, 10:01 ET The 3rd Annual Newark Summit for Real Estate, Economic Development & Placemaking Returns February 9th
Mutlu, Founder & Principal, INOA ArchitectureMarcus Randolph, President & CEO, Invest NewarkSiree Morris, Managing Partner, MCI CollectiveMelanie Walter, Executive Director, New Jersey Housing & Mortgage Finance AgencyAndrew Cavaluzzi, Partner & Co-Founder,
More news about: The Newark Summit by roundtable&advisory
Jan 06, 2026, 12:44 ET Mazda publica sus resultados de ventas de diciembre y los sólidos resultados de ventas del año completo 2025
recursos empresariales de los empleados de Mazda donaron $96,000 a causas importantes para los empleados de la empresa.Mazda Canada, Inc. (MCI) registró ventas en diciembre de 4,932 vehículos, lo que supone un incremento del 8 % en comparación con diciembre del año pasado. Las ventas anuales
More news about: Mazda North American Operations
Jan 06, 2026, 06:22 ET BLA for subcutaneous formulation of Leqembi® accepted in China
in the United States under the brand name Leqembi Iqlik™.Eisai estimates that there were 17 million patients with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease in China in 2024, which is expected to increase with the aging of the population.Leqembi is the result
More news about: BioArctic
Jan 05, 2026, 10:58 ET Mazda Reports December Sales and Strong Full-Year 2025 Sales Results
addition, Mazda's Employee Business Resource Groups donated $96,000 to causes important to the company's employees.Mazda Canada, Inc., (MCI) reported December sales of 4,932 vehicles, an increase of 8 percent compared to December last year. Full-year 2025 sales increased 13.2 percent, with
More news about: Mazda North American Operations
Dec 17, 2025, 13:56 ET Laura L. Lott Named New Executive Director of the National Art Education Association
inclusion initiatives to reshape national standards and practices across the museum community. Lott began her career at the National Geographic Society and MCI Foundation igniting her lifelong passion for supporting innovative K–12 education programs."I am honored to join NAEA and support the educators
More news about: National Art Education Association
Dec 08, 2025, 18:44 ET Leqembi included in China's commercial insurance innovative drug list
Drug List is scheduled to take effect on January 1, 2026.Eisai estimates that there were 17 million patients with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease in China in 2024, which is expected to increase with the aging of the population.Eisai launched Leqembi
More news about: BioArctic
Dec 08, 2025, 18:42 ET Leqembi included in China's commercial insurance innovative drug list
Drug List is scheduled to take effect on January 1, 2026.Eisai estimates that there were 17 million patients with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease in China in 2024, which is expected to increase with the aging of the population.Eisai launched Leqembi
More news about: BioArctic
Dec 08, 2025, 06:00 ET Maple Leaf Foods Announces Special Dividend
capital needs, and relevant governance and tax considerations. These considerations include the 2017 Governance Agreement with McCain Capital Inc. ("MCI") and Michael H. McCain, which caps MCI's ownership in Maple Leaf Foods at 45%, as well as commitments made as part of the Canada Packers Inc. spin-off
More news about: Maple Leaf Foods Inc.
Dec 06, 2025, 15:05 ET AV-Comparatives triomphe à l'édition 2025 du « Tiroler Innovationspreis »
AV-Comparatives a présenté la première plateforme évolutive de test et de certification de l'IdO en Europe. En collaboration avec des chercheurs de MCI Innsbruck, ils ont mis au point un système robuste et automatisé conçu pour évaluer la cyber-résilience des appareils connectés, conformément à la législation
More news about: AV-Comparatives
Dec 06, 2025, 15:02 ET AV-Comparatives triumphiert beim „Tiroler Innovationspreis 2025"
IoT‑SicherheitsstandardsAV‑Comparatives präsentierte damit die erste skalierbare IoT‑Test- und Zertifizierungsplattform Europas. Gemeinsam mit Wissenschaftlern des MCI Innsbruck entwickelten sie ein robustes, automatisiertes System zur Bewertung der Cyber‑Resilienz von vernetzten Geräten, auch im Einklang mit der kommenden
More news about: AV-Comparatives